Higher preconception maternal and paternal vitamin B12 was tied to fewer birth defects in a Shanghai cohort of 3032 couples.
|Articles|April 1, 2011
Warning for lopinavir/ritonavir oral solution
The US Food and Drug Administration has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.
Advertisement
The US Food and Drug Administration (FDA) has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.
Lopinavir/Ritonavir oral solution is an antiviral medication containing alcohol and propylene glycol that is used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV-1) infection .
Preterm neonates have a decreased ability to eliminate propylene glycol, which could lead to adverse events including serious heart, kidney, and respiratory problems.
Advertisement
Related to this article
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.
Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.
Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.
Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.
A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.
Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adolescents with symptomatic oHCM.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
2
First-in-human trial tests microneedle stamp approach for peanut allergy
3
What the Camzyos approval means for adolescents with obstructive HCM
4
FDA approves tiratricol as first treatment for peripheral thyrotoxicosis in MCT8 deficiency
5